Is it safe to give Augmentin (amoxicillin‑clavulanate) and azithromycin concurrently to an adult without liver disease, renal impairment, cardiac arrhythmias, or use of other QT‑prolonging drugs?

Concurrent Use of Augmentin and Azithromycin: Safety Assessment

Yes, concurrent use of Augmentin (amoxicillin-clavulanate) and azithromycin is generally safe in adults without cardiac risk factors, liver disease, renal impairment, or concurrent QT-prolonging medications, though careful monitoring is warranted due to azithromycin's potential for QT prolongation.

Key Safety Considerations

QT Prolongation Risk with Azithromycin

The primary concern with azithromycin is its potential to prolong the QT interval, though the absolute risk in low-risk patients is modest:

• Azithromycin carries an FDA warning for QT prolongation and increased risk of cardiac arrhythmias 1
• Multiple cardiology guidelines list azithromycin among drugs that can prolong the QT interval and should be avoided with other QT-prolonging agents 2
• In patients without concurrent QT-prolonging drugs, a large real-world study found no increased cardiac event risk with azithromycin versus amoxicillin (OR 1.08,95% CI 0.98-1.20 at 5 days) 3

Critical Drug Interaction Concern

The most important safety issue is concurrent use with OTHER QT-prolonging medications:

• When azithromycin was used with other QT-prolonging drugs, the odds of cardiac events increased significantly (OR 1.40,95% CI 1.04-1.87) 3
• ACC/AHA/HRS guidelines specifically list azithromycin among drugs that interact with amiodarone and other antiarrhythmics to increase QT prolongation risk 2
• British Thoracic Society guidelines state patients taking QT-prolonging agents should not receive macrolide therapy 2

Augmentin Safety Profile

Augmentin itself does not prolong the QT interval and has no significant cardiac interactions:

• Amoxicillin-clavulanate has a well-established safety profile over 20+ years of clinical use 4
• The primary adverse effects are gastrointestinal disturbances and hypersensitivity reactions 5
• No cardiac conduction abnormalities are associated with Augmentin monotherapy

Clinical Algorithm for Safe Concurrent Use

Pre-Treatment Assessment Required:

1. Obtain baseline ECG to measure QTc interval 2

   • QTc >450 ms (men) or >470 ms (women) is a contraindication to azithromycin 2

2. Review complete medication list for other QT-prolonging drugs 2

   • Common culprits: antiarrhythmics, antipsychotics, certain antidepressants, ondansetron, fluoroquinolones
   • If present, strongly consider alternative to azithromycin 3

3. Check electrolytes, particularly potassium and magnesium 2

   • Hypokalemia and hypomagnesemia increase torsades de pointes risk 2
   • Correct abnormalities before initiating therapy

4. Assess cardiac history 2

   • History of arrhythmias, heart failure, or structural heart disease increases risk
   • Family history of sudden cardiac death warrants caution 2

Monitoring During Therapy:

• ECG monitoring is not routinely necessary in low-risk patients receiving short-course therapy 2
• For hospitalized or high-risk patients, consider repeat ECG 2-3 days after initiation 2
• Discontinue azithromycin if QTc exceeds 500 ms during treatment 2

Special Populations

Age Considerations:

• Elderly patients (60-79 years) have increased risk of QT prolongation with azithromycin 6
• No increased cardiac event risk was found in patients ≥65 years in the large cohort study, but caution remains warranted 3

Renal Impairment:

• Augmentin requires dose adjustment in severe renal dysfunction (CrCl <30 mL/min) 5
• Azithromycin should be used with caution in patients with GFR <10 mL/min 1
• Hemodialysis patients have significantly increased sudden cardiac death risk with azithromycin (HR 1.70 vs amoxicillin-based antibiotics) 7

Hepatic Impairment:

• Both drugs should be used cautiously in hepatic dysfunction 1, 5
• Baseline liver function tests recommended before azithromycin initiation 2

Common Pitfalls to Avoid

1. Failing to screen for concurrent QT-prolonging medications - this is the single most important modifiable risk factor 3

2. Assuming all macrolides are equivalent - clarithromycin has more drug interactions via CYP3A4 inhibition than azithromycin 2

3. Overlooking electrolyte abnormalities - correct hypokalemia and hypomagnesemia before initiating therapy 2

4. Using azithromycin in hemodialysis patients without careful consideration - this population has markedly elevated cardiac risk 7

Bottom Line

For the patient described (adult without liver disease, renal impairment, cardiac arrhythmias, or other QT-prolonging drugs), concurrent Augmentin and azithromycin is safe. The combination is commonly used in clinical practice for community-acquired pneumonia and other respiratory infections 4. However, obtain a baseline ECG if the patient has any cardiac risk factors, and maintain a low threshold for discontinuing azithromycin if QTc prolongation develops or if other QT-prolonging medications need to be added during treatment 2.